Thinking of joining a study?

Register your interest

NCT05696834 | Active, not recruiting | Orthopedic Disorder


Sclerotherapy and Bone Marrow Injection In Aneurysmal Bone Cyst
Sponsor:

Al-Azhar University

Information provided by (Responsible Party):

Abdullah Musa Alwani Hassan

Brief Summary:

Aneurysmal bone cysts (ABCs) are benign, locally destructive growing bone tumors, which were first described in 1942 by Jaffé and Lichtenstein (1). They are most often diagnosed in childhood and early adulthood. The literature reports that ABCs comprise 1-6% of all primary benign bone tumors (2). Most cases of ABCs (75-90%) are reported for patients younger than 20 years, with a slightly higher incidence for females (3). Most common localizations are the pelvis, the metaphysis of long bones and the spine, but ABCs can also affect any other localization(2). ABCs that are associated with a preexisting osseous lesion are defined as secondary ABCs. They represent approximately 30% of all ABCs (2). Secondary ABCs can occur, e.g., in cases of a giant cell tumor, chondroblastoma or telangiectatic osteosarcoma

Condition or disease

Orthopedic Disorder

Intervention/treatment

Sclerotherapy With Adjuvant Bone Marrow Injection In Management of Aneurysmal Bone Cyst

Detailed Description:

The clinical symptoms of an ABC are usually accidently discovered or may consist of pain and swelling in the affected region and pathological fractures ( complete and incomplete ) can be observed occasionally. In conventional radiography a relatively well-defined osteolytic, expansile lesion with possible blowout of the periosteum and a soap-bubble appearance can be found (4). MRI scanning shows cystic formations with typical fluid-fluid levels due to blood sedimentation (7). Because of the possible rapid growth with local destruction, the literature describes cases of ABCs that mimic malignant bone tumors}}

Study Type : Observational
Estimated Enrollment : 20 participants
Official Title : Sclerotherapy With Adjuvant Bone Marrow Injection In Management of Aneurysmal Bone Cyst
Actual Study Start Date : March 1, 2023
Estimated Primary Completion Date : January 2025
Estimated Study Completion Date : December 2025

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 1 Year
Sexes Eligible for Study: All
Criteria
Inclusion Criteria
  • All Patients above age of 1 year.
  • The affected area was all bones except skull, ribs, and other non-orthopedic specialties.
  • Primary or recurrent ABC
  • Incomplete Fractured affected bones as greenstick fracture.
  • Healed Pathological fracture without any surgical intervention
Exclusion Criteria
  • ABC. In skull, ribs, and other non-orthopedic specialties.
  • Age less than 1 year
  • Suspected malignancy or other bone cysts
  • Complete fractured bones and healed pathological fracture with surgical intervention.

Sclerotherapy and Bone Marrow Injection In Aneurysmal Bone Cyst

Location Details


Please Choose a site



Sclerotherapy and Bone Marrow Injection In Aneurysmal Bone Cyst

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations


Not yet recruiting

Egypt,

Faculty of Medicine Al-Azhar University Assuit

He said, Egypt,

Loading...